| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1.2K Cr | 4.1% | 23.3% |
| Total Income | 1.2K Cr | 2.9% | 23.4% |
| Expenditure | 951.61 Cr | 7.5% | 25.1% |
| PBT | 218.61 Cr | 13.2% | 16.3% |
| Net Profit | 164.24 Cr | 13.4% | 16.0% |
| OPM | 23.02% | 2.59pp | 0.58pp |
| NPM | 14.04% | 2.64pp | 0.88pp |
| EPS | 17.86 | 12.8% | 40.8% |
Growth solid, margins below guide; recovery hinges on H2 delivery
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 EBITDA 23% vs 24–28% guidance (missed). Reaffirmed full-year guidance without cutting; executing on sequential growth (12 quarters positive, though some via lower-margin geographies).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
eClerx delivered 23% YoY revenue growth and crossed $500M run rate, meeting top-quartile aspiration, but Q1 EBITDA margin of 23% sits 100 bps below guidance floor (24–28%), driven by wage increments and geographic mix headwinds. PAT declined 13.4% QoQ despite 4.1% revenue growth, signalling acute margin compression. Management reaffirmed full-year EBITDA guidance, banking on post-increment recovery, but Q1 miss raises execution risk. BFSI, a large segment, remains essentially flat YoY. Near-term recovery depends on H2 margin expansion + sequential growth re-acceleration; downside if macro stalls or wage normalization doesn't offset.
₹1152.4 Cr
Revenue · +23.3% YoY₹164.2 Cr
Reported PAT · +16% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Sequential revenue growth 2.8%, strong execution
OVERSTATEDDelivered 4.1% INR sequential growth; management cited USD 2.8% (understating in INR terms)
Operating EBITDA 23% margin, delivered healthy profitability
OVERSTATED23% OPM delivered; but PAT down 13.4% QoQ despite revenue +4.1% — margin compression acute
Wage increments 210 bps drag on EBITDA, strong growth offset impact
MET260 bps EBITDA compression Q-o-Q, wage contribution 210 bps; math checks. But 23% is 100 bps below 24% guidance floor
BFSI flat QoQ, gradient moving positive, H2FY27 recovery expected
METBFSI -0.1% YoY (technically flat); Q4 was -2.8% YoY, so Q1 is an improvement. Trend real but still below zero
Analytics crossed $100M run rate, 7% sequential growth — well ahead of company average
METConsistent with 2.8% company sequential growth; 7% for segment is credible
Confident FY27 EBITDA 24–28% range achievable
MISSQ1 = 23%, 100 bps below range floor. Management banking on post-increment margin recovery, not yet proven
Earnings quality
What changed since the last call
EBITDA margin miss guidance
DowngradeGuidance 24–28%, Q1 delivered 23% — 100 bps below floor. Management attributed to increments (210 bps) + infrastructure (40 bps) + geographic mix (–60 bps S&D offset). Margins expected to recover sequentially once increments done.
BFSI recovery delayed, but gradient improving
NeutralQ4 was –2.8% YoY, Q1 is –0.1% YoY — improvement directional. But still not positive. Management now guiding H2FY27 inflection (vs. prior silence on timing).
AI momentum & non-FTE model gaining traction
UpgradeAnalytics +7% sequential (above company average). AI discussions accelerating; agentic solutions rolled into productized services. QA 360 win shows delivery proof-of-concept. Management more vocal on AI ROI timeline (still vague: 'icing on cake' → 20–25% of revenue medium-term ambition unstated).
Emerging business (F&A) sustaining strong growth
UpgradeFourth consecutive quarter of strong growth; expanding F&A into APAC (mid-market traction). Differentiator vs. softness in M&D, Retail, CMT.
The Q&A
Analysts pressed hard on BFSI weakness (Yash Goenka, Girish Pai, others). Management defended with gradient argument (–2.8% to –0.1%) and H2 recovery thesis, but tone was defensive. On ACV decline, Girish Pai challenged 'top-quartile' claim vs. trending-down ACV; Kapil deferred to large-deal focus & industry recognition. Few held firm pushback on margin miss or macro risk; most accepted management's post-increment recovery narrative without demanding proof.
BFSI growth recovery — Yash Goenka, Awriga Capital
PartialGradient moving positive; H2FY27 expected to see momentum build and benefits start.
Tech services headcount investment — Yash Goenka, Awriga Capital
DodgedMix of AI COE, pilots, product enhancements. Tech & Analytics growing 7% (above company). Hard to link X headcount to Y ROI; focus on growth momentum, conversions, and margin 24–28% target.
Headcount decline signal — Sandeep Shah, Equirus Securities
PartialQuarter-on-quarter variations; billed headcount up; confident on full-year top-quartile growth.
ACV momentum sustainability — Sandeep Shah, Equirus Securities
PartialFY26 delivered $170M ACV; aspire to do at least that and grow on it for FY27–28 tailwind. No reasons to not march toward that goal.
BFSI mortgage opportunity — Rahul Jain, Dolat Capital
AnsweredTwo clients, US, servicing side. Early traction; focus on successful pilots before scaling.
FX impact on margins — Shradha Agrawal, AMSEC Securities
AnsweredYes, FX provided ~50 bps Q-o-Q margin benefit. Excluding FX, QoQ impact would have been 330 bps.
Offshore regulation monitoring — Shradha Agrawal, AMSEC Securities
AnsweredNo further change from last quarter guidance. CMT Q1–Q4 growth drop (7% to 1.3%) is quarterly aberration, not regulatory.
Top 5 clients slow growth — Shradha Agrawal, AMSEC Securities
AnsweredNot slow; clients implementing technology/AI. FCC work dependent on client refreshes and regulatory environment. Financial services regulatory environment less onerous than 2–3 years back; hence lower refresh demand.
AI platform for CX in BFSI — Vamshi Krishna, Kotak Securities
PartialProprietary QA 360 platform being invested in; partnerships with hyper-scalers; ATR business IP for audit; agent assist. Working with client-led tech platforms. Experimentation and testing role for eClerx.
Margin trajectory with diversification and G&A hikes — Vamshi Krishna, Kotak Securities
AnsweredDepends on growth. FY26 had 5%+ sequential growth; margins improved sharply. FY26 ended at 27% (above midpoint). Now advise midpoint (26%) as reasonable; above that will be difficult.
Agentic AI industry growth drivers — Sandeep Shah, Equirus Securities
AnsweredClients investing massively in AI, seeking ROI proof. Tech transformation drives scale/consolidation. ROI still unproven; lots of promise but commitments still to materialize. Yes, pricing pressure, but nothing extraordinary vs. business-as-usual.
BFSI contact center and voice/non-voice mix — Sandeep Shah, Equirus Securities
PartialMixed feedback; clients reducing non-voice or increasing voice depending on journey. Traditionally eClerx non-voice >> voice; not worried if increases. Comfortable zone between both.
Three-year capex and revenue guidance — Vinit Thakur, Plus91 AMC
PartialCapEx ~₹130–150 Cr FY27. Three-year depends on Board decisions, finalized in next budget. Revenue: top-quartile growth (vague; peers not all reported yet).
Segment growth outlook — Vinit Thakur, Plus91 AMC
AnsweredEmerging (F&A) continue; BFSI must turn; CMT, Hi-Tech confident growth; Fashion/Luxury small, modest growth expected.
AI impact on headcount — Vinit Thakur, Plus91 AMC
AnsweredAI is opportunity; clients need partners understanding business + tech mindset. Billed headcount up despite total headcount down (utilization play). No headcount concern.
Roll-off trends and AI adoption — Dipesh Mehta, Emkay Global
AnsweredRoll-off volatile; generally 15–20% of annual revenue in 4-quarter average. Expect that to hold FY27.
CMT and Fashion seasonality — Dipesh Mehta, Emkay Global
AnsweredCLX Q2 is soft but H1 vs H1 comparison up YoY. FY27 for CLX expected 0–2% (slight improvement). Roll-off on short-term work not fully predictable.
Non-top-10 client slowdown — Rohit Thorat, Axis Capital
PartialQuarter-on-quarter volatility; strong directional focus on growing outside top 10 to reduce concentration. Confident in higher growth outside top 10 going forward.
Other operating expenses increase — Rohit Thorat, Axis Capital
AnsweredCommunication, network infrastructure, facility buildout (G&A). Trend expected to persist; equipment more expensive. CapEx elevated this quarter; OpEx also higher. Should see normalization as revenue grows.
Outcome-based and non-FTE model conversions — Chirag Shah, White Pine Investments
DodgedDiscussions on AI-led deals (SEC, transaction monitoring, fraud, retail mortgages). Momentum higher than 2–3 quarters prior. Deal sizes small; 'icing on cake.' Can it be 25–30% in 12–18 months? Don't know; but leads to higher conversions and mind share.
Path to $1B and strategy — Girish Pai, BOB Capital Markets
AnsweredGood momentum in capability areas; expanded geographies with traction; adjacent areas (mortgages, wealth); F&A moving mid-market. No fundamental shift required; continue investing in sales, delivery, tech/AI.
ACV trending down despite top-quartile growth claim — Girish Pai, BOB Capital Markets
PartialFocus on large deals; industry recognition helping. $40M–$41M Q1; aspire >$170M full year (vs. $170M FY26). Substantial YoY growth. Thesis still holds.
Margin trajectory with scale to $1B — Girish Pai, BOB Capital Markets
AnsweredWant to stay in 24–28% range. Pivot to tech/analytics (growing faster, being invested in). If can get 30–40% revenue from tech/analytics despite competitive pressure, should hold margins in range.
BFSI weakness vs. peers — Girish Pai, BOB Capital Markets
PartialQ4 –2.8% YoY to Q1 –0.1% YoY; gradient positive. With pipeline momentum and conversions, confident to turn around H2FY27.
Cross-selling progress and wallet growth — Varun Bang, Bandhan Life Insurance
AnsweredBoth. CX in FS, MarTech in CMT, Compliance Manager examples. Service kit relevant across segments. Need to win new logos, grow outside top 10, increase wallet in top 10, cross-sell across service lines & locations.
$500M milestone and deal size eligibility — Varun Bang, Bandhan Life Insurance
AnsweredYes, absolutely. Analyst recognition bringing inbound leads. Seeing increase in deal size. Thesis holds; confident in larger deals.
Organic vs. inorganic growth path — Varun Bang, Bandhan Life Insurance
AnsweredIndustry-leading growth = organic focus. Open to acquisitions if timing, capability, synergy, culture, price align. Nothing to announce now; constantly looking.
Guidance
Full-year FY27 top-quartile growth (25%+ inferred vs. peer cohort)
MediumBased on 23.3% YoY Q1 delivery and 'top-quartile' claim; some peers not yet reported. Management reiterating but not quantifying full-year revenue target explicitly.
Sequential growth expected to continue Q2 and beyond
MediumQ1 +4.1% QoQ achieved; management confident on Q2 sequential growth. Depends on BFSI recovery and no macro stall.
Operating EBITDA margin 24–28% full-year FY27
LowQ1 delivered 23%, 100 bps below floor. Management confident margin recovery post-increment; claims no reasons for doubt. But new center ramp (lower margins) and G&A inflation (networking, compute) are ongoing drags.
Margins expected to improve sequentially from Q2 onwards
MediumPost-Q1 increments, wage cost absorption easier. Revenue growth should flow through; but depends on commodity cost (network, equipment) not inflating further and mix not worsening.
FY27 CapEx ₹130–150 Cr (annualized ~3.2% of revenue)
HighNew facility buildout (India centers: Mumbai, Pune, Chandigarh, Mohali, Coimbatore) + 1,600 seat additions over 3–4 months. Depreciation/interest costs rising Q1 due to new asset base.
Risks the call surfaced
Segment concentration & BFSI underperformance
HighBFSI segment flat/negative for 2 quarters; material segment for eClerx. Other peers reporting strong BFSI growth; eClerx lagging. Recovery guided for H2FY27 but unproven.
Margin compression from geographic diversification
MediumNew centers (Cairo, Lima, Manila) operate at 'lower gross margin than India.' Headcount doubled in Manila (15 months); revenue mix shift has 'downside on margin.' Q1 EBITDA 23% already 100 bps below 24–28% guidance.
Macro uncertainty & client spending selectivity
MediumManagement notes 'macroeconomic environment remains mixed'; clients 'continue to be selective in their spending.' M&D and Retail weak (supply chain challenges from Middle East conflict). CMT volatility (7% to 1.3% QoQ). Fashion/Luxury small and soft. Sequential growth guidance at risk if macro stalls.
Wage inflation & cost pressures persist
MediumQ1 wage increments accounted for 210 bps EBITDA margin compression. G&A costs (networking, compute, infrastructure) rising. Management expects margin recovery post-Q1 but ongoing capex depreciation and facility costs will continue to pressure margins.
AI ROI still unproven at scale
LoweClerx investing heavily in AI COE, pilots, agentic solutions, but ROI and conversion to large revenue still nascent. Management admits 'deal sizes in AI relatively small' and role is 'icing on cake.' Risk that AI investments don't convert to outsized returns.
Management
Score 7/10. Clear on metrics and segment narratives; transparent on cost drivers (wage, G&A, FX). But evasive on timeline for BFSI recovery and AI ROI quantification. Reaffirms guidance (24–28% EBITDA) despite Q1 miss, suggesting confidence or optimism bias. 12 consecutive quarters of sequential growth; 23.3% YoY revenue growth; crossed $500M run rate. But Q1 EBITDA 23% (miss), PAT –13.4% QoQ (concerning), BFSI two quarters weak. Mixed track record — growth yes, but profitability pressure emerging.
1 · H2 FY27
BFSI segment expected to turn positive; margin recovery with revenue growth
2 · Q2 FY27
Analytics QA 360 pilot go-live at scale (~0.5M interactions/month audited); Coimbatore center ramp
3 · Q2–Q3 FY27
New delivery center capacity (1,600 seats) across India becomes operational; easing utilization ceiling
Near-term recovery depends on H2 margin expansion + sequential growth re-acceleration; downside if macro stalls or wage normalization doesn't offset.
Growth Intact, Margins Below Guide—Recovery Unproven
eClerx delivered 23.3% YoY revenue growth and crossed $500M run rate, meeting top-quartile aspiration. But Q1 EBITDA margin at 23% sits 100 bps below guidance floor, and net profit fell 13.4% quarter-on-quarter despite 4.1% revenue growth. Management reaffirmed full-year guidance, betting on post-increment margin recovery—the market is skeptical.
₹1152.4 Cr
+23.3% YoY, +4.1% QoQ
23%
–100 bps vs 24–28% guide
₹164.2 Cr
+16% YoY, –13.4% QoQ
$41M
+25% YoY
The tension: growth met, margins missed
eClerx hit the growth target. Revenue of ₹1152.4 Cr, up 23.3% YoY, aligned with management's 'top-quartile' aspiration, and the company extended its sequential-growth streak to 12 consecutive quarters. Crossing $500M annual run rate and posting 4.1% QoQ expansion is solid macro absorption. But the income statement reveals the real tension: EBITDA margin of 23% sits 100 bps below the 24–28% guidance floor, and far more troubling, net profit declined 13.4% quarter-on-quarter despite revenue growing 4.1%. That divergence—headline growth momentum offset by severe margin compression—is the story of Q1.
What broke on the cost side
Management attributed the 260 bps EBITDA margin compression QoQ to wage increments (210 bps), infrastructure investment (40 bps), and an unfavorable revenue mix shift from new centers entering at lower gross margins. The wage impact is structural; management's post-increment recovery thesis was priced in. The geographies (Cairo, Lima, Manila) are long-term levers. But the near-term headwind is pronounced. Even accounting for FX tailwind (~50 bps from rupee depreciation), organic margin compression was 330 bps. Management reaffirmed the full-year EBITDA guidance of 24–28% without walking down the range, betting on post-increment leverage and revenue growth—a bet that requires proof.
Sequential growth 2.8%, strong execution
Delivered 4.1% INR (management cited 2.8% USD—understating in rupee terms)
Supported
Operating EBITDA 23%, healthy profitability
23% delivered but 100 bps below 24% floor; PAT –13.4% QoQ despite revenue +4.1%
Overstated
Wage increments 210 bps drag; growth offsetting impact
Math checks (210 bps + 40 bps infra + mix = 260 bps). But recovery timing unproven.
Supported but incomplete
BFSI flat QoQ, gradient moving positive, H2FY27 recovery expected
–0.1% YoY (vs –2.8% Q4)—directional improvement but still negative
Supported but defensive
Analytics crossed $100M run rate, 7% sequential growth
Consistent with company 2.8% sequential; 7% for segment is 2.5× average
Supported
Confident FY27 EBITDA 24–28% achievable, no reasons for doubt
Q1 = 23%, 100 bps below floor. No quantified recovery roadmap or phase-by-phase guidance
Contradicted
What changed on this call
Margin miss published: Guidance 24–28%, Q1 delivered 23%—first time below guidance range in years. Management framed as temporary (post-increment recovery) but offered no revised trajectory or phased midpoint target.
BFSI recovery timeline crystallized: Segment was –2.8% YoY in Q4, now –0.1% in Q1. When pressed, management conceded H2FY27 as the inflection point. This is a large segment (~30–35% of revenue) soft for two quarters; peers report strong BFSI growth, raising relative execution risk.
Analytics & AI momentum confirmed: Positive inflection. Segment crossed $100M annual run rate and posted 7% sequential growth (2.5× company average). QA 360 going live in Q2. Compliance Manager traction accelerating. This is the growth offset against BFSI headwind.
Emerging business (F&A) sustaining strength: Fourth consecutive quarter of robust growth; APAC expansion into mid-market SMB gaining traction. Standout performer while M&D, Retail, CMT soften.
How the market greeted the print
The stock opened down 2.37% on day 1 post-announcement. By day 3, the decline had widened to 8.06%—a significant fade suggesting the market was skeptical of management's reaffirmed guidance. By day 5, it had recovered slightly to –5.61%, but the tail-off is telling. At ₹1897 (as of Aug 14), the stock sits 24% below its all-time high and is above key moving averages (50-day, 200-day), but volume is trending downward. Foreign institutional investors trimmed holdings by 0.82 percentage points QoQ to 11.0% (domestic institutions also 0.11pp lower at 23.84%). The modest but notable institutional pullback, coupled with the day-3 price fade, signals professional skepticism toward management's margin recovery narrative. The market wants proof before re-rating upward.
12th consecutive quarter of sequential growth; top-quartile aspiration met on revenue
Margin miss 100 bps below floor; guidance reaffirmed without detail
Analytics & Emerging segments bright; AI/QA 360 live Q2
BFSI flat/negative 2 quarters; H2 recovery unproven
New centers ramping 1,600 seats across India; capacity headroom for growth
PAT down 13.4% QoQ despite revenue +4.1%—acute compression
Wage inflation structural but transient; recovery thesis plausible
Lower-margin geographies (Cairo, Lima, Manila) will persist as mix drag
ACV up 25% YoY; large-deal focus supporting top-quartile claims
Macro headwinds (M&D, Retail, CMT soft) create offset risk to sequential growth
Risks, ranked by concern to a holder
Margin recovery doesn't materialize post-Q1
HighQ1 EBITDA 23%, PAT down despite revenue growth. If Q2 doesn't show sequential improvement, full-year 24–28% target and stock credibility both break. Market will re-rate lower on permanent margin reset.
BFSI remains weak through H2 (three consecutive quarters negative)
HighMaterial segment (~30–35% of revenue), now –2 quarters, soft vs peers. H2 recovery is central to eClerx's narrative; if unproven, top-quartile growth weakens and concentration risk rises materially.
New center ramp margin drag persists; scale doesn't offset lower-margin mix
MediumCairo, Lima, Manila at lower gross margins than India. If these don't reach India equivalence within 18–24 months, geographic diversification becomes a margin ceiling, not a lever.
Macro stalls; sequential growth breaks the 12-quarter streak
MediumM&D, Retail, CMT already soft. If clients defer discretionary spend, sequential growth stalls. Loss of the streak would be a psychological reset for the stock.
Wage and G&A inflation persist; depreciation from elevated CapEx pressures margins further
MediumFY27 CapEx ₹130–150 Cr is elevated; depreciation will rise. If labor and infrastructure costs don't normalize, 24–28% EBITDA target may need reset downward.
AI platform conversions disappoint; deal sizes remain small
Low-MediumManagement invested heavily in AI COE, QA 360, Compliance Manager, but ROI unproven at scale. If conversions stay in 'icing on cake' territory, AI capex becomes a near-term margin drag.
ACV momentum slows; large-deal pipeline weakens
LowACV up 25% YoY but management aspires to only >$170M (vs $170M FY26—marginal). If deals weaken, top-quartile growth requires volume increases, pressuring margins further.
1 · BFSI inflection proof
Q2 BFSI growth rate is the linchpin. If flat/negative again, the H2 recovery thesis fails and management credibility cracks. A positive print (even +0.5–1% YoY) validates the gradient argument and buys time.
2 · EBITDA margin sequential improvement
Q2 EBITDA should improve from Q1's 23% (post-increment normalization). If it stays at or below 23%, full-year 24–28% guidance is broken. Midpoint (26%) would be minimum credibility threshold; anything below 24% forces reset.
3 · Analytics & AI conversion traction
QA 360 live in Q2; Compliance Manager pipeline maturation; first revenue contribution from platforms. If Analytics fails to sustain 7%+ sequential growth or platforms stall, eClerx's differentiation narrative weakens.
The number to track
Q2 EBITDA margin—not revenue growth (that's been solid) and not net profit (opex leverage is the issue). Margin is the acid test. If Q2 shows sequential improvement toward 24%+, the recovery narrative holds and the stock has a floor. If flat or lower, the full-year 24–28% target is broken and eClerx re-rates to a lower-margin peer set. This is a steady-execution story, not step-change; margins are the proof.
eClerx is a high-quality franchise executing well on growth. The 23.3% YoY revenue expansion, 12-quarter sequential streak, and $500M run-rate achievement are genuine. Analytics and Emerging segments are bright spots; AI/QA 360 pathway is credible. But Q1 EBITDA miss—100 bps below guidance—and PAT QoQ decline despite revenue growth are not noise. They signal cost pressures (wage, infrastructure, mix) are outpacing scale benefits in the near term. Management's reaffirmed guidance is defensible on a 12-month horizon but requires Q2 proof. The market's day-3 8% fade and FII trimming reflect justified skepticism. Until margins recover, this is a hold for believers in the long-term $1B, 30–40% tech-analytics thesis, with material downside if BFSI doesn't inflect or margin recovery stalls.